Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Enterprise Value (2021 - 2026)

Rani Therapeutics Holdings' Enterprise Value history spans 7 years, with the latest figure at -$36.3 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 192.34% to -$36.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$36.3 million, a 192.34% decrease, with the full-year FY2025 number at -$10.1 million, down 347.41% from a year prior.
  • Enterprise Value came in at -$36.3 million for Q1 2026, down from -$10.1 million in the prior quarter.
  • The five-year high for Enterprise Value was $17.2 million in Q3 2022, with the low at -$88.4 million in Q4 2022.
  • Historically, Enterprise Value has averaged -$12.2 million across 5 years, with a median of -$2.3 million in 2024.
  • Biggest five-year swings in Enterprise Value: skyrocketed 135.66% in 2023 and later plummeted 4870.77% in 2025.
  • Year by year, Enterprise Value stood at -$88.4 million in 2022, then surged by 107.6% to $6.7 million in 2023, then plummeted by 133.68% to -$2.3 million in 2024, then tumbled by 347.41% to -$10.1 million in 2025, then tumbled by 258.46% to -$36.3 million in 2026.
  • Business Quant data shows Enterprise Value for RANI at -$36.3 million in Q1 2026, -$10.1 million in Q4 2025, and -$8.3 million in Q3 2025.